COMPLETES RESTRUCTURING OF CLOSE TO 95% TRANSGENOMIC LIABILITIES NEW HAVEN, Conn., March 13, 2018 (GLOBE NEWSWIRE) — Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced today it has settled its lawsuit with Crede Capital Group LLC, restructuring the final substantial liability of legacy payables inherited as part of the merger with Transgenomic in June 2017. These... Read more
Company Renamed Precipio, Inc.–To Commence Trading On NASDAQ Under The New Ticker “PRPO” NEW HAVEN, Conn. and OMAHA, Neb., (June 30, 2017) – Precipio Diagnostics, LLC and Transgenomic Inc. (OTCQB: TBIOD) today announced the closing of their previously announced merger. In connection with the transaction, Transgenomic has changed its name to Precipio, Inc. Precipio’s common stock... Read more
Distinguished Experts in Disease Diagnosis and Diagnostics Technology Bring World Class Scientific Acumen and Insight to Help Guide the New Merged Company’s Expansion and Growth Other Recent Pre-Merger Developments Include EPO Decision to Grant Patent Protection in Europe for Transgenomic’s Multiplexed ICE COLD-PCR and Completion of Reverse Stock Split NEW HAVEN, Conn. and OMAHA, Neb.,... Read more
OMAHA, Neb. (June 13, 2017) — Transgenomic, Inc. (OTCQB: TBIO) today reported that the European Patent Office (EPO) has confirmed its intention to grant a patent covering multiplexed ICE COLD-PCR (MX-ICP) technology in the European Union (EU). This Dana-Farber Cancer Institute patent is exclusively licensed to Transgenomic. Paul Kinnon, President and CEO of Transgenomic, commented,... Read more
Proceeds Intended to Facilitate Completion of Merger with Precipio Diagnostics During Second Quarter of 2017 OMAHA, Neb. (April 17, 2017) — Transgenomic, Inc. (OTCQB: TBIO) today reported that it has received $1.15 million in proceeds from a note bridge financing.The financing is intended to help facilitate the completion of Transgenomic’s merger with Precipio Diagnostics, LLC,... Read more